These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28550080)

  • 61. Multidisciplinary education approach to optimize phosphate control among hemodialysis patients.
    Chan MW; Cheah HM; Mohd Padzil MB
    Int J Clin Pharm; 2019 Oct; 41(5):1282-1289. PubMed ID: 31302884
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
    Rombolà G; Londrino F; Corbani V; Falqui V; Ardini M; Zattera T;
    J Nephrol; 2012; 25(4):490-6. PubMed ID: 22476966
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Calcium carbonate powder as a phosphate binder.
    Miller D; Taber TE; Hegeman TF
    ASAIO Trans; 1989; 35(3):322-4. PubMed ID: 2597473
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group.
    Weinreich T; Passlick-Deetjen J; Ritz E
    Am J Kidney Dis; 1995 Mar; 25(3):452-60. PubMed ID: 7872324
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oral phosphate binders in CKD - is calcium the (only) answer?
    Goldsmith D; Covic A
    Clin Nephrol; 2014 Jun; 81(6):389-95. PubMed ID: 25017668
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.
    Ruggeri M; Bellasi A; Cipriani F; Molony D; Bell C; Russo D; Di Iorio B
    J Nephrol; 2015 Oct; 28(5):593-602. PubMed ID: 25027030
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis.
    Spoendlin J; Paik JM; Tsacogianis T; Kim SC; Schneeweiss S; Desai RJ
    JAMA Intern Med; 2019 Jun; 179(6):741-749. PubMed ID: 31058913
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy.
    Fukagawa M; Kasuga H; Joseph D; Sawata H; Junge G; Moore A; Akiba T
    Clin Exp Nephrol; 2014 Feb; 18(1):135-43. PubMed ID: 23670305
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
    Finn WF;
    Clin Nephrol; 2006 Mar; 65(3):191-202. PubMed ID: 16550750
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
    Isaka Y; Hamano T; Fujii H; Tsujimoto Y; Koiwa F; Sakaguchi Y; Tanaka R; Tomiyama N; Tatsugami F; Teramukai S
    J Am Soc Nephrol; 2021 Mar; 32(3):723-735. PubMed ID: 33547218
    [TBL] [Abstract][Full Text] [Related]  

  • 71. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
    Scialla JJ; Kendrick J; Uribarri J; Kovesdy CP; Gutiérrez OM; Jimenez EY; Kramer HJ
    Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
    Goto S; Komaba H; Moriwaki K; Fujimori A; Shibuya K; Nishioka M; Kim JI; Yoshiya K; Shin J; Hasegawa H; Taniguchi M; Fujii H; Nishi S; Kamae I; Fukagawa M
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1375-84. PubMed ID: 21551021
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
    Ittel TH; Schäfer C; Schmitt H; Gladziwa U; Sieberth HG
    Klin Wochenschr; 1991 Jan; 69(2):59-67. PubMed ID: 2027271
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia.
    Shigematsu T; Une Y; Ikejiri K; Kanda H; Fukagawa M; Akizawa T
    Am J Nephrol; 2021; 52(6):496-506. PubMed ID: 34098559
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The role of short daily hemodialysis in the control of hyperphosphatemia, secondary hyperparathyroidism and anemia.
    Jiang JL; Ren W; Li Y; Liu GY; Zhou CP; Su KL; Chen W; Wang K; Ni LJ; Hu Z
    Int Urol Nephrol; 2013 Dec; 45(6):1725-31. PubMed ID: 23591723
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients.
    Tonelli M; Wiebe N; Culleton B; Lee H; Klarenbach S; Shrive F; Manns B;
    Nephrol Dial Transplant; 2007 Oct; 22(10):2856-66. PubMed ID: 17906326
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.
    Block GA; Rosenbaum DP; Leonsson-Zachrisson M; Åstrand M; Johansson S; Knutsson M; Langkilde AM; Chertow GM
    J Am Soc Nephrol; 2017 Jun; 28(6):1933-1942. PubMed ID: 28159782
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients.
    d'Almeida Filho EJ; da Cruz EA; Hoette M; Ruzany F; Keen LN; Lugon JR
    Sao Paulo Med J; 2000 Nov; 118(6):179-84. PubMed ID: 11120549
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients.
    Almirall J; Betancourt L; Esteve V; Valenzuela MP; López T; Ruiz A; Martínez-Ocaña JC; Calvet X
    Int Urol Nephrol; 2012 Feb; 44(1):231-6. PubMed ID: 21069570
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2008 Feb; 12(1):55-61. PubMed ID: 18257813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.